Summit Therapeutics Inc.
$24.32
▼
-7.81%
2026-04-22 10:12:13
www.smmttx.com
NGM: SMMT
Explore Summit Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$18.91 B
Current Price
$24.32
52W High / Low
$36.91 / $13.83
Stock P/E
—
Book Value
$0.85
Dividend Yield
—
ROCE
-161.37%
ROE
-2.06%
Face Value
—
EPS
$-1.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
265
Beta
-1.37
Debt / Equity
3.17
Current Ratio
9.87
Quick Ratio
9.87
Forward P/E
-16.83
Price / Sales
—
Enterprise Value
$14.56 B
EV / EBITDA
-13.3
EV / Revenue
—
Rating
Buy
Target Price
$30.82
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 2. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 3. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 4. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 5. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 6. | Jade Biosciences, Inc. | $23.5 | — | $1.13 B | 0% | -34.07% | -89.19% | $100.1 / $6.57 | $6.74 |
| 7. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -224.88 M | -234.21 M | -568.44 M | -66.85 M | -65.59 M | — |
| Net Profit | -219.17 M | -231.79 M | -565.71 M | -62.91 M | -61.2 M | — |
| EPS in Rs | -0.28 | -0.3 | -0.73 | -0.08 | -0.08 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.7 M |
| Operating Profit | -1.09 B | -210.98 M | -88.73 M | -63.62 M |
| Net Profit | -1.08 B | -221.31 M | -614.93 M | -78.78 M |
| EPS in Rs | -1.39 | -0.29 | -0.79 | -0.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 751.18 M | 435.56 M | 202.95 M | 664.17 M |
| Total Liabilities | 92.32 M | 46.81 M | 125.26 M | 537.51 M |
| Equity | 658.86 M | 388.75 M | 77.69 M | 126.65 M |
| Current Assets | 720.3 M | 423.75 M | 189.71 M | 656.71 M |
| Current Liabilities | 72.99 M | 41.73 M | 20.41 M | 38.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -322.93 M | -142.11 M | -76.76 M | -41.58 M |
| Investing CF | -174.31 M | -205.34 M | -587.77 M | -0.62 M |
| Financing CF | 617.53 M | 381.23 M | 86.51 M | 620.24 M |
| Free CF | -323.59 M | -142.25 M | -76.89 M | -42.21 M |
| Capex | -0.66 M | -0.14 M | -0.13 M | -0.62 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 64.01% | -680.54% | — | — |
| Profit Margin % | — | — | -11174.75% | — |
| Operating Margin % | — | — | -9024.26% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -10371.35% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.